In the present study, we presumed that PD-L1 expression and CD8+TILs as well as ALK status may be associated with biologic behavior of IMT, and expected that immune check point inhibitor might be beneficial to the patients with ALK-negative IMTs. The gene discussed is CD274; the disease is inflammatory myofibroblastic tumor.